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Summary
How T cells translate T cell receptor (TCR) recognition
of almost identical pMHC ligands into distinct biologi-
cal responses has remained enigmatic. Although dif-
ferences in affinity or off rate are important, they offer
at best an incomplete explanation. By using Fo¨rster
resonance energy transfer (FRET), we have visualized
the ligand-induced interaction between OT-I TCR and
CD8. We found that both recruitment of TCR to the
immunological synapse and the TCR-CD8 interaction
induced by weak agonists (positive-selecting ligands)
was delayed but not necessarily weaker than strong
agonists (negative selectors). A delayed and perhaps
longer lasting CD8-TCR interaction results in delayed
phospho-ERK recruitment to the synapse. The kinet-
ics of the TCR-CD8 interaction can reconcile previ-
ously anomalous data, where biological activity did
not correlate with TCR-pMHC binding kinetics for cer-
tain ligands. Our findings indicate that the T cell trans-
lates antigen recognition into T cell responses by dif-
ferential recruitment of CD8 to the TCR.
Introduction
Activation of mature T cells and differentiation of devel-
oping thymocytes requires ligation of the T cell receptor
(TCR) by peptide-MHC (pMHC) complexes. The TCR
signaling machinery can somehow distinguish between
pMHC ligands that differ by even a single amino acid and
translates this into different effector functions (Gas-
coigne et al., 2001; Germain, 2001). Altered peptide
ligands (APLs) are peptide variants derived from the
original antigenic peptide, with substitutions at particu-
lar residue(s). APLs can be grouped into different cate-
gories: full agonists, which are capable of complete
T cell activation; weak or partial agonists; antagonists (li-
gands that can inhibit the activity of agonist); and others
that do not stimulate the T cell (nonstimulatory ligands).
The strength of interaction between TCR and pMHC is
a major factor in determining the fate of developing T
cells (Alam et al., 1996), but this is also influenced by
many other factors including the amount of coreceptor,
pMHC density, and variation in amounts of negative reg-
ulators such as CD5 (Starr et al., 2003; Werlen et al.,
2003). Strong agonists are typically recognized by the
TCR with relatively high affinity and/or a long half-life.
At least in class I-restricted systems, strong agonists
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Cancer Center, University of Texas, Houston, Texas 77030.cause negative selection, whereas lower-affinity ligands,
either weak agonists or antagonists, cause positive
selection of TCR transgenic thymocytes in fetal thymic
organ culture (FTOC) (Alam et al., 1996, 1999; Chidgey
and Boyd, 1998; Hogquist et al., 1994, 1995; Holmberg
et al., 2003; Jameson et al., 1994; Sebzda et al., 1996).
Models for how T cells are activated by low numbers
of antigenic pMHC and how they are able to distinguish
between different pMHCs generally fall into those based
on kinetic proofreading, where discrimination between
ligands is based on kinetic parameters, primarily the
half-life of TCR-pMHC binding, and those that invoke ar-
chitectural or conformational changes in the signaling
complex (Germain, 2001). The general correlation be-
tween biological activity and TCR-pMHC binding half-
life is predicted by kinetic proofreading, but there are
numerous exceptions to this correlation (Gascoigne
et al., 2001). In contrast, there is little evidence from
TCR structures supporting conformational change as
a means to differentiate between ligands, with the ex-
ception of one crystal structure that shows conforma-
tional changes in the Ca domain of pMHC bound TCR
compared to unliganded TCR, in a region predicted to
interact with CD33 (Kjer-Nielsen et al., 2003). Other
data suggest that binding of an agonist or negative
selecting ligand, but not of a positive-selecting ligand,
exposes a normally hidden SH3 binding site in CD33
that then binds to the signaling adaptor molecule, Nck
(Gil et al., 2002; Risueno et al., 2006).
In addition to the TCR signal, the coreceptors, CD4 on
T helper cells and CD8 on cytotoxic T cells (CTL), are
crucial in thymocyte development and are generally re-
quired for effective T cell activation. For CD8+ cells,
this coreceptor modulates the strength of signaling
through the TCR by delivering CD8-associated Lck to
the TCR complex (Veillette et al., 1988). The coreceptors
also enhance adhesion by binding to nonpolymorphic
regions of pMHC (Gao et al., 1997; Norment et al.,
1988). Both of these molecular associations are thought
to contribute to stabilization of TCR-pMHC complex.
They have a role in discrimination between different
types of ligands in that interfering with the ability of
coreceptor to interact with the TCR-pMHC complex
converted an agonist into a partial agonist (Madrenas
et al., 1997). Also, the amount of CD8 in the thymocytes
determined whether a given T cell clone is positively or
negatively selected (Starr et al., 2003; Werlen et al.,
2003). We have previously shown that close proximity
between coreceptor and TCR is induced by agonist
pMHC but not by nonstimulatory or antagonist ligands
(Gascoigne and Zal, 2004; Yachi et al., 2005; Zal et al.,
2002). So far, there has not been a study correlating
the interaction between TCR and coreceptor with
TCR-pMHC binding kinetics and T cell activation by dif-
ferent APLs. Several APLs for the OT-I TCR have been
particularly well defined in terms of their activation or an-
tagonism of mature CD8+ T cells and for their ability to
induce positive and negative selection in thymic devel-
opment (Hogquist et al., 1994, 1995; Jameson et al.,
1994; Rosette et al., 2001). Moreover, the solution
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these different pMHC complexes, and ‘‘outliers’’ were
identified from the otherwise compelling correlation be-
tween the affinity and half-life of pMHC-TCR complexes
and the biological outcomes (Alam et al., 1996, 1999;
Gascoigne et al., 2001; Rosette et al., 2001).
Fo¨rster (or fluorescent) resonance energy transfer
(FRET) microscopy allows us to quantitate the extent
and kinetics of molecular interactions between fluoro-
phore-tagged proteins within a subcellular region such
as the immunological synapse (Zal and Gascoigne,
2004). FRET works only between molecules less than
w10 nm apart, making it useful to show molecular inter-
actions in a nondestructive way. To this end, we have
measured the kinetics of TCR-CD8 interaction by using
FRET between CD8b-yellow fluorescent protein (YFP)
and CD3z-cyan (C)FP, during recognition of a range of
APLs in the OT-I T cell system. We found that different
APLs induce quantitatively and qualitatively different
CD8-TCR interaction profiles. Weaker agonists induced
FRET between CD8 and TCR slower than the full ago-
nist. The slower kinetics correlated with delays in the ap-
pearance of phosphorylated kinase ERK (pERK) at the
synapse. Moreover, the kinetics and magnitude of
TCR-CD8 interaction induced by different APLs, includ-
ing ‘‘outlier APLs,’’ correlated better with their biological
strength than the kinetics of corresponding TCR-pMHC
interaction in solution. Thus, the T cell uses different
kinetics of CD8 recruitment to the TCR to translate al-
tered antigen recognition signals into distinct functional
responses.
Results
Bioactivity of APLs in the OT-I System
Chimeric CD8b-YFP (Yachi et al., 2005) and CD3z-CFP
(Zal et al., 2002) genes were retrovirally introduced into
CD8-negative OT-I hybridomas previously transfected
with wild-type CD8a, giving rise to a stable cell line
(OT-I.ZC.8bY). Enhanced cyan fluorescent protein
(ECFP) and enhanced yellow FP (EYFP) are a well-char-
acterized donor-acceptor pair of fluorescent proteins
for FRET microscopy (Yachi et al., 2005; Zal and Gas-
coigne, 2004; Zal et al., 2002). The OT-I TCR recognizes
an ovalbumin-derived peptide (OVA) presented by
H-2Kb and a series of APLs with single amino acid sub-
stitutions. The activation (agonist or antagonist), thymo-
cyte selection (negative or positive) phenotypes, and so-
lution binding kinetics for these APLs are summarized in
Table S1 (in the Supplemental Data available with this
article online). The relationship between the biological
activity of these APLs and their solution binding kinetics
is good, but not complete: e.g., A2 is 10%–20% the
strength of OVA, but still a strong agonist (Hogquist
et al., 1995). However, Kb-A2 binds OT-I TCR with
a slightly higher affinity and longer half-life than does
Kb-OVA (Alam et al., 1999). G4 is a weak agonist and
an antagonist that gives positive selection in FTOC. It
is inefficient at inducing early responses in T cells, but
gives strong responses at late time points (Rosette
et al., 2001). It has very slow association and dissocia-
tion rates, i.e., its half-life is much longer than the strong
agonists.Equal Opportunity Antigen Presentation
In order to separate the effect of peptide structure from
the surface density of pMHC, we used RMA-S cells as
antigen-presenting cells (APC). These cells are deficient
in the Tap2 peptide transporter and therefore unable to
express properly folded MHC class I complexes. How-
ever, at a below-physiological temperature, they can ex-
press labile Kb or Db molecules, which can then be sta-
bilized by exogenously added peptide, rendering them
stable when the temperature is raised to 37C (Ljungg-
ren et al., 1990). Different peptides have different abili-
ties to stabilize the pMHC complexes on the cell surface;
so, to ensure that the T cells are presented with equiva-
lent numbers of pMHC complexes on the cell surface for
all the APLs to be tested, we titrated the peptides and
determined the loading concentration of peptide that
resulted in equivalent cell-surface Kb expression, as
previously described (Figure 1A; Holmberg et al., 2003;
Yachi et al., 2005). The pMHC expressions remained
stable for more than 60 min (data not shown).
High-Affinity Ligands Induce CD3z Recruitment
Faster than Lower-Affinity Ligands
To relate earlier biological data on APLs to our assays,
we tested the ability of the different peptides to induce
TCR downregulation, T-APC conjugate formation, and
the recruitment of TCR and CD8 to the synapse. TCR
downregulation in the OT-I.ZC.8bY T hybrids was tested
with RMA-S cells loaded to equivalent pMHC density
(Figure 1B). OVA downregulated TCR with very fast ki-
netics: 50% downregulation was achieved in less than
20 min, and maximum (>95%) downregulation by 90
min. The strong agonist A2 downregulated TCR as
strongly as OVA, with very slightly slower kinetics. The
weak agonist or antagonist G4 never fully downregu-
lated TCR, reaching a plateau ofw60% downregulation
by 2 hr. The antagonist E1 showed very weak TCR
downregulation, plateauing at 15% at 90 min. (E1 may
also be considered a very weak agonist in that it can
sensitize target cells for weak CTL-mediated killing
[Hogquist et al., 1994].) The pure antagonist R4 showed
no more than 6% downregulation even after 3 hr, and
nonstimulatory peptide VSV gave no marked TCR down-
regulation. The ability of these APLs to cause endocyto-
sis of the TCRs correlated well with the qualitatively
different functional responses that they induce.
Formation of conjugates between the T cells and
RMA-S cells presenting the different APLs was com-
pared by flow cytometry. Cy5-labeled RMA-S cells were
loaded with peptides and mixed with OT-I.ZC.8bY cells.
T-APC conjugates were counted by comparing events
positive for both YFP (OT-I.ZC.8bY) and Cy5 (RMA-S
cells) to the total number of OT-I.ZC.8bY cells (Fig-
ure 1C). Most of the ligands showed a similar time
course of conjugate formation, peaking at 15–20 min,
with the number of conjugates being in proportion to
the relative strength of the ligands in T cell activation.
Note that all of the APLs and the nonstimulatory peptide
VSV promoted conjugate formation compared to RMA-S
cells without added peptide. We have shown previously
that several different endogenous nonstimulatory pep-
tides promote conjugate formation similarly to VSV
(Yachi et al., 2005).
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(A) In order to compare recognition of equivalent numbers of pMHC for each of the APLs, RMA-S cells were loaded with different peptides by
incubating the cells at 29C at the indicated concentrations, and subsequently at 37C to destroy empty MHC molecules. These concentrations
had been determined by titration to give equal H-2Kb density, as demonstrated by Kb Ab staining. This staining was performed with each exper-
iment.
(B–D) OT-I.ZC.8bY cells were allowed to interact at 37C with RMA-S cells expressing the same pMHC density of the different peptides as
indicated. At various times, cells were fixed, stained, and analyzed.
(B) T cells were stained with Vb5 Ab, and TCR expression was assessed by flow cytometry. The TCR expression is shown normalized to expres-
sion on T cells incubated with RMA-S cells in the absence of peptide (100%). Staining with an isotype control Ab was defined as 0%. The results
are representative of at least three independent experiments.
(C) The time course of T-APC cell conjugate formation with different APLs was determined by flow with Cy5-labeled RMA-S cells. Cells were fixed
and conjugate formation was assessed by counting the percentage of cell couples positive for both YFP and Cy5. The results are representative
of at least three independent experiments.
(D) Conjugates were sorted as in (C) and imaged to determine the recruitment of CD3z-CFP and/or CD8b-YFP into the contact interface, in com-
parison to the unengaged part of the cell. The cells were grouped according to their recruitment of CD3z-CFP and CD8b-YFP, those with both
molecules in excess in the synapse compared to the rest of the cell (black bars), those with recruitment of CD8b-YFP but not CD3z-CFP (gray
bars), and those where neither of the molecules was at an increased level compared to the nonsynapse part of the cell (white bars). For each
group, n > 29 cells (average of 46 cells). Results are representative of at least two independent experiments.TCR-CD3z recruitment to the synapse requires initial
stimulation through TCR. Therefore, we quantitated
how the kinetics of CD3z-CFP recruitment correlate
with APL strength. T-APC conjugates were sorted as in
Figure 1C and imaged to assess the recruitment of
CD3z-CFP and CD8b-YFP to the synapse. The cell cou-
ples were triaged into those with recruitment of both
CD8 and CD3z, those with recruitment of CD8 alone,
and those showing recruitment of neither CD8 nor
CD3z to the synapse. We did not observe cells that re-
cruited CD3z but not CD8. A much smaller proportion
of cells made conjugates in response to the weak li-
gands such as VSV, compared to the strong ligands
such as OVA, so that data on CD3z and CD8b recruit-
ment for VSV could only be obtained for these relatively
rare cells. The strong agonists recruited CD3z to the syn-
apse area earlier than did the weaker agonists (Fig-
ure 1D). E1 gave very weak and delayed CD3z recruit-
ment. The antagonist R4 and the nonstimulatory VSV
recruited CD3z over background only in rare instances
and only at later time points. Therefore, there wasa good correlation between TCR recruitment to the syn-
apse and the biological response, although G4 showed
delayed kinetics, as with conjugate formation and TCR
endocytosis, perhaps related to its slow on and off rates.
Delayed CD8-CD3z Interaction Induced
by Weaker Agonists
We compared the FRET signals induced between CD3z-
CFP and CD8b-YFP by the different agonist and antag-
onist APLs for the OT-I TCR. Cy5-labeled RMA-S cells
were loaded with the different APLs and incubated
with OT-I.ZC.8bY cells. The cells were fixed at different
times and imaged, and FRET efficiency was measured
in the regions of intercellular contacts (Figures 2 and 3;
Yachi et al., 2005; Zal and Gascoigne, 2004). Note that
these measurements are made, as for the CD8b and
CD3z recruitment experiments described above, on in-
dividual cell-cell conjugates. Thus, for some peptides,
this represents data from the low proportion of cells
that actually made conjugates, compared to the rela-
tively large proportion of cells that made conjugates in
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OT-I hybridomas expressing CD8a wild-type, CD3z-CFP, and CD8b-YFP (OT-I.ZC.8bY) were incubated with Cy5-stained RMA-S cells express-
ing equivalent amounts of Kb loaded with the different APLs: (A) OVA, (B) A2, (C) G4, (D) E1, (E) R4, or (F) VSV. The top row of each panel shows
mid-cell sections of fluorescence images (CD8b-YFP in red, CD3z-CFP in green, and Cy5 in blue in the merge column), and donor-ratioed, com-
pensated FRET efficiency images in the right column. See scale bar for color coding. The bottom row of each panel shows en face projections of
the T cell-APC interface and donor-ratioed compensated FRET images (right column). The contact areas between T cell and APC were defined in
3D by the overlap of Cy5 and YFP or CFP fluorescence. Original magnification:363. The results are representative of at least three independent
experiments.response to OVA. Such analysis emphasizes molecular
events on a single-cell level while the overall outcome
will be further magnified by differences in the degree
of conjugate formation. As described before, the nonsti-
mulatory peptide VSV did not increase the FRET signal
in T-APC conjugates, whereas the agonist OVA induced
a fast FRET response peaking 10–12 min after initiation
of contact formation (Yachi et al., 2005).
The prototype OVA peptide and the APLs reported to
have agonist, antagonist, and/or positive selection activ-
ity—A2, G4, E1, and R4—all, at various time points, in-
duced in synapses a degree of FRET, hence proximity
of CD3z-CFP to CD8b-YFP above the steady basal signal
seen with VSV-loaded RMA-S cells (Figures 2 and 3).
OVA induced by far the highest immediate increase in
FRET at 5 min (the earliest point that could be measured)
and peaked at 10 min (Figure 3A). In general, the induc-
tion of CD3z proximity to CD8 was lower and/or slower
by APLs than by OVA. The next strongest agonist, A2,
showed only slightly lower initial CD3z-CD8 interaction
at 5 min and a delayed maximum compared to OVA.
The magnitude of the interaction was lower than OVA
and weaker than might have been predicted from its
high-affinity binding in vitro. The weak agonist or antag-
onist G4 did not induce substantial FRET at 5 min but fol-
lowed slowly to a strong peak of interaction at 20 min
that was as strong as that induced by OVA at 10 min
(Figure 3A). Antagonist E1 induced a similar time course
of CD3z-CFP proximity to CD8b-YFP as G4, i.e., late ac-
cumulation at 20 min but with a weaker signal (Figure 3B).
The pure antagonist R4 induced even lower late FRET
signals, but clearly higher than VSV (Figure 3B). There
were statistically significant differences between re-
sponses to all the peptides at one time point at least,
except between A2 and E1 (Figure 3C). The finding that
A2 did not induce a strong early TCR:CD8 interaction
could explain why it is a weaker agonist than OVA, de-
spite the slightly stronger binding of Kb-A2 to the OT-I
TCR (Alam et al., 1999). Thus, the time course of TCR-
CD8 FRET correlated with the phenotype of the APL in
inducing positive or negative selection.APL Independence of CD8-pMHC Interaction
At this point, we had to consider the possibility that CD8
might bind to different APL-MHC complexes with differ-
ent affinities. For example, the CD8 interaction with
Kb-A2 could be weaker than for Kb-OVA. However, this
appeared unlikely given that the CD8 binding site on
MHC is far removed from the peptide binding groove
(Gao et al., 1997). To test the TCR-independent binding
of CD8 to Kb peptides, we used the TCR-deficient
58a2b2 T hybridoma-expressing CD8a wild-type and
CD8b-YFP (CD8+) or YFP alone (CD82). These cells
were mixed with Cy5-labeled RMA-S cells expressing
the same amounts of Kb with the various peptides and
used in a conjugate assay as above. In the absence of
added peptide, the CD8+ cells did not bind to the
RMA-S cells (Figure 4A). The CD82 cells did not bind to
the RMA-S cells with or without peptide. Thus, the cell:
cell binding assay measured MHC class I and CD8-de-
pendent binding. We found that there was no substantial
difference in CD8-dependent binding to any of the Kb
peptides (Figure 4A). Therefore, the differences between
APLs in the induction of FRET between CD3z and CD8
were not trivial and had to involve TCR binding.
CD8 Dependence of A2 Stimulation
Because of the early but weaker interaction between
CD8b and CD3z induced by A2 compared with OVA, de-
spite its relatively ‘‘strong’’ phenotype as an agonist and
its high-affinity TCR binding in vitro, we wondered
whether recognition of A2 by OT-I TCR might somehow
be independent of CD8 function. We took a short-term
cultured line of ex vivo OT-I CTL and activated them
with A2 or OVA in the presence of various concentra-
tions of blocking CD8a mAb. The response to A2 was
substantially more sensitive to blocking by CD8 anti-
body than the response to OVA. Similar results were ob-
tained with another CD8a mAb (53-6.7, data not shown).
These data indicate that OT-I activation by A2 is even
more dependent than OVA on the coreceptor CD8 and
that the weaker FRET response to A2 than to OVA was
not due to CD8 independence of A2 recognition.
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with CD8-CD3z Interaction
CD8 is thought to increase signal transduction by bring-
ing its associated Lck molecule to the TCR complex, in
order to phosphorylate the immunoreceptor tyrosine-
based activation motifs (ITAM) on CD3 and ZAP-70 mol-
ecules. Phosphorylation of the MAP kinase ERK is far
downstream of Lck signaling, part of the Ras signaling
pathway, and has been shown to be an important corol-
lary of signaling for positive or negative selection in
thymocyte development (Werlen et al., 2003). In addi-
tion, ERK phosphorylation is an important component,
with SHP-1, of positive and negative feedback loops in
Figure 3. Delayed and Reduced Interaction between CD8 and CD3z
with Weaker Ligands
(A and B) OT-I.ZC.8bY cells were allowed to interact with OVA, A2,
G4, E1, R4, or VSV peptide-loaded RMA-S cells, and the cells were
fixed at the indicated time points. FRET efficiency was assessed
from the contact interface of the two cells as described for Figure 2.
The results are shown as average FRET efficiency6 SEM for nR 17
(average of 29 cells, except R4 5 min, n = 11). p < 0.05 for OVA 10 min
and G4 20 min compared to all other peptides at those time points.
(C) p values < 0.05 for comparisons between different peptides are
shown for each time point. The data are representative of two inde-
pendent experiments.T cell signaling (Stefanova et al., 2003). Therefore, we
wanted to compare the synapse-proximal CD8-CD3z in-
teraction data with the downstream induction of pERK.
OT-I.ZC.8bY cells were incubated with RMA-S cells ex-
pressing different Kb-peptide complexes for different
times at 37C. After fixing and permeabilization, the cells
were stained for pERK and the signal was quantitated in
the synapse (Figure 5). For OVA, the absolute amount of
pERK at the synapse increased to a peak at w20 min,
then declined (Figure 5C). However, when we compared
this to a plot of the ratio of pERK in the synapse com-
pared to nonsynapse regions of the membrane of the
same cells (pERK polarization to the synapse; Fig-
ure 5D), the peak was earlier. Thus, pERK was concen-
trated at the synapse earlier than the maximum amount
of pERK was produced. The weaker agonists A2 and G4
showed lower amounts of pERK in the synapse than
with OVA, and they in turn had higher amounts than
the antagonists, which were barely increased relative
to nonstimulatory VSV (Figure 5C). Comparison of these
ligands by means of pERK polarization to the synapse as
a measure (Figure 5D) showed that available pERK was
Figure 4. Comparison of APLs in Supporting Kb-CD8 Binding and
CD8 Dependence of A2
(A) The different APLs were tested for their ability to support cell-cell
adhesion mediated by CD8-MHC class I interaction. TCR-negative
58a2b2 hybridomas expressing CD8a wild-type and CD8b-YFP
(gray bars) or 58a2b2 expressing YFP (open bars) were allowed to
interact with Cy5-labeled RMA-S cells expressing the same density
of different pMHC for 1 hr at 4C. The cells were fixed and conjugates
counted by flow. The results are presented as mean6 SD, n = 3, and
are representative of three independent experiments.
(B) OT-I CTL were incubated 6 various concentrations of inhibitory
CD8a (CT-CD8a) Ab and tested at an effector:target ratio of 5:1
with 51Cr-labeled EL-4 cells that had been peptide loaded with 20
nM OVA or 80 nM of A2. These amounts of peptide had been deter-
mined by titration to give an equivalent amount of CTL killing in the
absence of CD8 Ab. The results are shown as mean6 SD, n = 3, and
are representative of three independent experiments.
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Synapse Correlates with the Strength of the Induced TCR-CD8
FRET Response, rather than with Biological Activity
OT-I.ZC.8bY cells were allowed to interact with RMA-S cells ex-
pressing the same amounts of the different pMHC for various times,
then fixed and stained for pERK-1 and pERK2.
(A) The localization of pERK at the synapse with RMA-S cells pre-
senting OVA. In the merge column, CD8b-YFP is shown in red and
pERK in green, and therefore yellow shows colocalization.
(B) Same as (A) except VSV peptide was used.
(C) The pERK intensity at the synapse compared to membrane of
a nonstimulated cell. Background (bkg) was determined from
a cell-free area of the field. For each cell, (average pixel intensity
at synapse2 bkg)/(average intensity at membrane of nonstimulated
cell 2 bkg) was calculated. Determined from n > 11 cells for each
peptide per time point (average of 22 cells).
(D) Polarization of pERK in the synapse compared to the nonsy-
napse cell surface of the same cell, from the same images as (C).
For each cell (average intensity at synapse2 bkg)/(average intensity
of a similar-sized nonsynapse region of cell surface 2 bkg) was
calculated. OVA and A2 are significantly different (p < 0.05) from all
the other peptides (except from each other) at 15 min (indicated
by **). G4 is significantly different from all the other peptides at
20 min (*). The experiment is representative of at least two indepen-
dent experiments.concentrated in the synapse with the same time course
for the two strong agonists (negative selectors) OVA and
A2, even though A2 induced a lower amount of pERK.
The peak of polarization to the synapse was the same
for the weak agonist (positive selector) G4, but was de-
layed compared to OVA or A2, as seen for the FRET re-
sponse. The kinetics of the ratio for antagonist E1 were
also similar to the FRET time course. Overall, these data
indicate that the time course of the FRET response
(TCR-CD8 interaction) is more closely related to the
biological activity than is the strength of the FRET signal:
i.e., strong agonists and negative selectors peak early
and positive selectors peak later, although antagonists
induce relatively little FRET compared to agonists. The
time course of concentration of pERK in the synapse
correlates with the FRET time course and bioactivity,
whereas the amount of pERK that concentrates in the
synapse is proportional to agonist strength. This is in
accord with data showing the role of pERK and SHP-1
in defining an antagonist versus an agonist signal
(Stefanova et al., 2003).
Discussion
We show here that the recruitment of TCR-CD3z and
CD8 to the synapse and the induction of the CD3z and
CD8 interaction contribute to the biological activity of in-
dividual APLs. There was a time delay before the induc-
tion of this interaction for some peptides, which was
longer for weaker agonists. Similarly, the weaker ligands
showed a delay in recruitment of pERK to the synapse
compared to strong agonists. We measured molecular
interaction between TCR-CD3z and CD8 by using FRET
between fluorescent proteins attached to their intracel-
lular domains. We used the fundamental measure of
FRET, efficiency (E), defined as the proportion of all
donor excited states that are transferred to acceptor
(Zal and Gascoigne, 2004) to detect an increase in donor
proximity to acceptor. We previously demonstrated that
the FRET signal between CD3z-CFP and CD8b-YFP is
specifically induced by antigen recognition and not sim-
ply caused by diffusion-driven interactions due to in-
creased crowding of the molecules (Yachi et al., 2005).
FRET was not increased by nonstimulatory ligands
alone, in synapses with similar amounts of TCR and cor-
eceptor (Yachi et al., 2005; Zal et al., 2002). FRET imag-
ing provides sensitive detection of fine differences in
protein interactions in subcellular compartments.
With most APLs, we observed a simple relationship
between solution binding kinetics, recruitment of CD3
and induction of CD3z-CD8b FRET within the synapse,
and the overall bioactivity of the ligand. For example,
OVA showed strong and early conjugate formation and
recruitment of both CD8 and CD3z to the synapse,
with induction of a strong FRET signal. OVA is a strong
agonist and negative selector and has a relatively high
affinity and long half-life for TCR binding. Similarly, the
antagonists and positive selectors E1 and R4 have lower
affinities and shorter half-lives than OVA (Alam et al.,
1996) and induced weak FRET responses. It is perhaps
noteworthy that E1 is not only a stronger antagonist than
R4, but also a very weak agonist (Hogquist et al., 1994).
In agreement, E1 gives an earlier and stronger FRET
response than R4. This relatively simple relationship
APL-Induced Interaction between CD8 and TCR
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CD8b-CD3z FRET induction, and the biological outcome
of stimulation by the APL, does not hold in all cases. G4
is an interesting intermediate APL in the OT-I system. It
can act as agonist and antagonist, giving positive selec-
tion in FTOC. However, it stimulates OT-I cells only at
high concentration and after long time periods com-
pared to OVA stimulation (Rosette et al., 2001). It has
a very long half-life and very slow association rate com-
pared to OVA. Its time course for T-APC conjugate for-
mation, CD3z recruitment, and FRET was delayed in
comparison to OVA, yet the FRET signal was as strong
as that of OVA. These data suggest that the slow induc-
tion of CD3z-CD8 interaction, and as a result the
slow T cell activation, is due to the slow on rate of the
TCR binding to Kb-G4. Once made, this interaction is
stable, supporting accumulation of interactions be-
tween the TCR-CD3 complex and CD8, and therefore
increased but delayed FRET response. Overall, this in-
terplay between TCR-pMHC binding and induction of
CD8b-CD3z interaction can explain the T cell activation
phenotype.
A different relationship between biological activity
and binding kinetics is shown by A2, which is only
10%–20% as strong an agonist as OVA, but has a similar
affinity and longer half-life (Alam et al., 1999). It is also
a weaker negative selector. Instead of complete deletion
of OT-I thymocytes, it selects cells with CD8aa rather
than CD8ab, which are unable to mount a strong
response to OVA (Hogquist et al., 1995). This type of
‘‘agonist selection’’ results in cells that are exiled to
patrol the far provinces of the T cell empire, such as
the gut and epithelium, to stand in the front line of
immune defense together with innate immune cells
(Cheroutre, 2004). Induction of CD8b-CD3z FRET was
weaker and slightly delayed compared to OVA, and rec-
ognition of A2 was more sensitive to CD8 Ab blocking.
Thus, the timing of TCR-CD8 interaction induced by A2
correlated with its biological properties despite anoma-
lous solution binding kinetics.
Although CD8 binds Kb-A2, the A2 peptide might
change Kb conformation so as to alter docking of CD8
or TCR, changing the architecture of the CD8-pMHC-
TCR complex and potentially reducing Lck activity.
The p2 residue is buried in the structure of Kb. Though
not available to the TCR, buried residues can influence
the structure of other parts of the peptide or of the sur-
face of the MHC (Fremont et al., 1995). Some OVA p2
variants affect Ab-defined Kb epitopes (Hogquist et al.,
1993). Although alanine at p2 does not alter these epi-
topes (K. Hogquist, personal communication), it is pos-
sible that conformational changes caused by A2 are
undetectable by the available Abs. In this context, it is
of interest that the TCR CDR2a binds Kb near p2. Subtle
changes in the binding position of CDR2a on pMHC
have been suggested to influence the CD8 dependence
of the TCR (Buslepp et al., 2003). Poor CD8 compatibility
for the TCR-pMHC complex could explain why the
solution binding is stronger than expected for the func-
tionality for this peptide. This supports the idea that the
ability to engage CD8 is somewhat peptide dependent
and, like TCR-pMHC binding, is important in distinguish-
ing pMHC complexes by TCR (Daniels and Jameson,
2000).Our data showed a time lag between conjugate forma-
tion, TCR recruitment to the synapse, and interaction
between CD8b and CD3z during recognition of some
APLs. This was clearest for functionally weaker APLs,
where TCR recruitment and TCR-CD8 interaction were
delayed compared to strong agonist. This time lag in
TCR-CD8 interaction and the dependence of the type
of signal (agonist, antagonist, etc.) on the induction of
the TCR-CD8 interaction fits well with a coreceptor ki-
netic proofreading model of T cell activation (Germain,
2001). This model predicts that certain biochemical
events occur at distinct times, so the timing of corecep-
tor and Lck recruitment to the TCR leads to distinct sig-
naling by the T cell. Therefore, TCR complex phosphor-
ylation at later time points by Lck leads to qualitatively
different signaling compared to early phosphorylation,
because other biochemical events interfere differently
with the signal. This model requires a time delay be-
tween the TCR’s encounter with pMHC before CD8
can interact with the TCR. We have directly shown that
there is a time lag and that it is prolonged for functionally
weaker APLs, as predicted by this model from their
lower TCR-pMHC affinities. The reduced FRET signal
for weaker APLs also agrees with this model, as the like-
lihood of forming a stable TCR-pMHC interaction able to
recruit CD8 reduces with weaker affinities. The impor-
tance of timing in initiation of the CD8-TCR interaction
can be understood through competing positive and neg-
ative feedback loops, such as that described between
ERK and SHP-1 (Stefanova et al., 2003). SHP-1 is re-
cruited to the TCR by antagonists, where it inactivates
Lck. Agonists activate ERK as well as SHP-1. Phospho-
ERK phosphorylates TCR-associated Lck on a serine
residue so that it cannot bind to pSHP-1. As ERK activa-
tion is downstream of Lck phosphorylation of CD3z,
CD8-Lck recruitment to the TCR plays an important
role in this feedback loop. The longer it takes for CD8-
TCR interaction to occur, and therefore for Lck to start
signaling leading to ERK activation, the more SHP-1
can be recruited to the TCR complex to inhibit any further
signaling.
We propose that the biological property of a given
pMHC is not governed solely by TCR binding but rather
by the composite ability to engage TCR and the core-
ceptor and to properly align the coreceptor and TCR in
this multimolecular complex. In other words, it is possi-
ble that a pMHC ligand may offer a good fit for TCR (as
seen by high affinity and/or long half-life), but at the
same time may compromise engagement of the core-
ceptor or the ideal membrane alignment between the
TCR and the coreceptor. Such a pMHC ligand would
then be a weaker agonist than a ligand that offers an op-
timal balance between binding of TCR and coreceptor
and their alignment in the membrane, even if that in-
volves a lower TCR affinity. This notion may help explain
why TCR affinities are so low. The affinities selected dur-
ing thymic selection ensure that the TCR has to take ad-
vantage of coreceptor in order to produce a functional
response, at least at low levels of antigen. This mecha-
nism ensures exquisite selectivity of T cell activation
by the appropriate class of MHC molecule and provides
a fail-safe mechanism to avoid inadvertent T cell activa-
tion by random cell-surface proteins or viral products
that happen to bind TCR with appropriate affinity. This
Immunity
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pMHC recognition differs from the prevalent view where
coreceptor is simply a passive enhancer of activation
and allows reconciliation of conflicting solution TCR-
pMHC binding data.
This study highlights the importance of CD8 being
a separate molecule from the TCR and its interaction
with TCR being inducible by pMHC: minor structural
changes in pMHC can cause significant changes in the
membrane alignment of the components in a multimo-
lecular complex, changing the likelihood of CD8-TCR
interaction and therefore the signaling outcome. Thus,
CD8 ensures that the TCR can specifically distinguish
between structurally very similar peptides via the kinet-
ics of CD8 recruitment to the TCR to translate the TCR-
pMHC interaction into a biological response.
Experimental Procedures
Reagents and Cells
Peptides were synthesized at the TSRI Core Facility and purified by
HPLC. The sequence of OVA is SIINFEKL, and APLs are specified by
the altered residue and its position in this sequence. Thus, G4 is
SIIGFEKL. The sequences of all the peptides used in this study are
presented in Table S1. Rabbit polyclonal anti-pERK1 and pERK2
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA),
goat anti (a)-rabbit IgG-Alexa680 from Molecular Probes (Eugene,
OR), aCD8a (CT-CD8a) from Caltag (Burlingame, CA), and aH-2Kb
(AF6-88.5) and aVb5 (MR9-4) from BDBiosciences (San Diego, CA).
Hybridomas expressing the OT-I TCR and CD8a were a gift of
E. Palmer (U. of Basel, Switzerland). They were made by retroviral
transfection of TCR-deficient 58a2b2 cells with the following genes
(with selection marker): OT-I a chain (G418), OT-I b-chain (puromy-
cin), and CD8a (histidinol). Cells expressing the appropriate cell-
surface proteins were FACS sorted and cloned (Stotz et al., 1999).
The CD8b-YFP (Yachi et al., 2005) and CD3z-CFP (Zal et al., 2002)
constructs have been described previously. In brief, CD8b and
CD3z were fused at their C termini with YFP or CFP, respectively,
with spacers between the two molecules to allow proper folding
and flexibility. These constructs were inserted into pBMN-Z, a retro-
viral expression vector based on LZRS-LacZ(A) (Kinsella and Nolan,
1996) without EBV sequences (http://www.stanford.edu/group/
nolan). Virus was produced from Phoenix packaging cells (gift of
G. Nolan) and used to infect OT-I cells as described (Yachi et al.,
2005). Cells were maintained in IMDM (OT-I) or RPMI (RMA-S) con-
taining 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin/streptomy-
cin, and 50 mM b-mercaptoethanol. For selection, 500 mg/ml G418
(for TCRa) and 3 mg/ml puromycin (for TCRb) were used. Because
optimal sensitivity of FRET with donor-ratioed sensitized emission
or E requires that the acceptor is not limiting, we used cells with a
donor:acceptor molar ratio of 1:1 to 1:3 calibrated by imaging and
comparison with a stoichiometric CFP-YFP construct.
Antigen-Presenting Cell Preparation
RMA-S cells were stained with Cy5 20 hr prior to experiments by in-
cubating cells with 0.1 mg/ml of Cy5 succinimidyl ester (Amersham
Biosciences, Bucks, UK) in RPMI at RT for 5 min, washing, and
quenching with 10% FCS in RPMI. The RMA-S cells were incubated
at 29C overnight, pulsed with peptides for 30 min at 29C, incu-
bated at 37C for 3 hr, and washed once.
TCR Downregulation and Conjugate Formation Assays
1 3 105 OT-I hybridomas and 1 3 105 peptide-pulsed RMA-S cells
were added to 96-well round bottom wells in a total volume of
50 ml and incubated for the indicated times at 37C. After incubation,
the cells were stained for Vb5 and examined by flow cytometry. The
data are shown as a percentage of Vb5 expression on the surface
of cells compared to cells incubated with RMA-S without peptide.
For the conjugate formation assay, the cells were pipetted up and
down three times after the incubation period before fixing in 2%
paraformaldehyde at indicated time points. After fixing for 12 minat RT, the cells were washed in PBS and the paraformaldehyde
was inactivated by 10 mM Tris (pH 7.4) in PBS for 5 min at RT. The
cell conjugates were examined by flow cytometry based on simulta-
neous expression of YFP (OT-I hybridoma) and Cy5 (Cy5-labeled
RMA-S cell).
CTL Assay for CD8 Dependency
OT-I CTLs were derived from stimulation of OT-I spleen cells for 5
days with peptide-pulsed irradiated (2000R) B6 spleen cells. A stan-
dard 51Cr-release assay was performed with 51Cr-labeled EL-4 cells.
EL-4 cells were loaded with either 20 mM of OVA peptide or 80 mM of
A2 for 1 hr. These levels were determined to give equivalent levels of
killing in titration experiments. Control targets included EL-4 cells in
the absence of peptide, non-51Cr-labeled EL-4 cells, 51Cr-labeled
EL-4 cells incubated with a lysis buffer. OT-I CTL were incubated
with varying concentrations of CD8a Ab (CT-CD8a) for 30 min on
ice before adding the EL-4 cells. Control effector cells were OT-I
CTLs without Ab. The assays were performed in 96-well round bot-
tom wells at a 5:1 effector:target ratio (105 CTLs with 2 3 104 EL-4
cells/well) in a total volume of 200 ml. The cells were incubated for
4 hr, and 100 ml was removed for counting.
Intracellular Staining for pERK
105 OT-I hybridomas and 105 peptide-pulsed RMA-S cells were
added to 96-well round bottom wells in a total volume of 50 ml and
incubated for the indicated times at 37C. Cells were fixed as de-
scribed above, washed, and permeabilized with 0.2% saponin in
PBS for 10 min at RT, then stained with pERK Ab for 1 hr. Cells
were washed twice with PBS-saponin, then stained with anti-rabbit
IgG-alexa680 for 45 min in a FACS buffer containing saponin,
washed, and mounted in Slowfade Light antifade mounting medium
(Molecular Probes) for imaging.
Microscopy
A system specifically designed for FRET microscopy was used, con-
sisting of Slidebook 4.0.3.9 software (3I Corp, Denver, CO) running
a Zeiss 200M microscope and two CoolSnapHQ cameras (Roper,
Tucson, AZ) attached through a beam-splitter (510LPXR, Chroma),
allowing simultaneous acquisition of donor and acceptor emission.
Rapid excitation switching was performed with a DG4 galvo illumi-
nator with a 300W xenon lamp (Sutter, Novato, CA). YFP excitation
was attenuated to 20% by dynamic positioning of the exit mirror.
Optical filters (Chroma) were: a common dichroic mirror JP4, YFPex
510/20 nm, YFPem 550/50 nm, CFPex 430/25 nm, CFPem 470/30
nm, Cy5ex 622/36 nm, Cy5em 700/75 nm. Exposure times were
0.2–0.8 s with 23 2 binning and Zeiss 633 1.4 Planapo oil objective.
Live cells were imaged in HEPES-buffered 199 (low autofluores-
cence: GIBCO, Grand Island, NY) with 5% FCS, no antibiotics, main-
tained at 37C by the FCS2 live imaging chamber and objective
heater (Bioptechs, Butler, PA). T cells and peptide-loaded RMA-S
cells were briefly mixed and added into a prewarmed imaging cham-
ber coated with poly-D-lysine (Sigma). For fixed cell imaging, the
cells were treated as above.
CFP, YFP Imaging, and FRET Analysis
A 3-filter set algorithm for calculation of FRET efficiency (E) was used
as described (Zal and Gascoigne, 2004; Zal et al., 2002). For each fo-
cal position, three exposures were registered: IDD (donor excitation/
emission), IAA (acceptor excitation/emission), and IDA (donor excita-
tion/acceptor emission, called CY). Background was subtracted
based on a user-specified, cell-free region of each image after soft-
ware flat-field correction. Images were registered with subpixel ac-
curacy with automated Slidebook software registration function.
The bleed-through coefficients of CFP into CY image and YFP into
CY image were calibrated with cells expressing either CD3z-CFP or
CD8b-YFP alone. YFP/CY bleed-through a = 8.8% and CFP/CY
bleed-through d = 63%. FRET efficiency was calculated as Eapp =
(IDA 2 a*IAA 2 dIDD)/(IDA 2 a*IAA 2 dIDD + GIDD) (Zal and Gascoigne,
2004; Zal et al., 2002). G = 3.5 6 0.1 (Gordon parameter) is the inde-
pendently calibrated ratio of sensitized emission in the IDA filter set
before photobleaching to donor recovery in the IDD filter set after
acceptor photobleaching (Gordon et al., 1998; Zal and Gascoigne,
2004). Cells with unusually high or low CD8b-YFP/CD3z-CFP ratios
(outside the 1:1 to 3:1 stoichiometric range), as well as movement
APL-Induced Interaction between CD8 and TCR
211artifacts, were excluded from analysis. The average FRET was
calculated from the contact interface. Statistical differences were
calculated by the mean difference hypothesis of Student’s two-
tailed t test assuming different variances and confidence level of
95%.
Supplemental Data
One Supplemental Table can be found with this article online at
http://www.immunity.com/cgi/content/full/25/2/203/DC1/.
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